Výsledky vyhledávání - "Jan Ouwerkerk"

Prevention and management of adverse events related to regorafenib

Autor: Chiara Cremolini, Carmen Roncero de Juan, Christine B. Boers-Doets, Kristina Vermeersch, Mieke De Wit, Jan Ouwerkerk, Alessandra Saettini, Ashley Bazin, SeeSee Juliana Raynard

Publikováno v: Supportive Care in Cancer
Supportive Care in Cancer, 22(3), 837-846

Regorafenib is an oral multikinase inhibitor that has shown antitumor activity in a range of solid tumors. Based on data from phase III clinical trials, regorafenib is indicated for the treatment of adult patients with metastatic colorectal cancer wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69353d28d34b4394904878ef0901e46
https://doi.org/10.1007/s00520-013-2085-z

Zobrazit plný text záznamu

Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch

Autor: Joel B. Epstein, Mario E. Lacouture, Ad A. Kaptein, Hans Gelderblom, Helen Gall, Jan Ouwerkerk, Johan W.R. Nortier, Jason M. Bredle, Natascha A.W.P. Schrama, Jan A.C. Brakenhoff, Christine B. Boers-Doets

Publikováno v: European Journal of Oncology Nursing, 17(6), 802-807
Boers-Doets, C B, Gelderblom, H, Lacouture, M E, Bredle, J M, Epstein, J B, Schrama, N A W P, Gall, H E, Ouwerkerk, J, Brakenhoff, J A C, Nortier, J W R & Kaptein, A A 2013, ' Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch ', European Journal of Oncology Nursing, vol. 17, no. 6, pp. 802-807 . https://doi.org/10.1016/j.ejon.2013.03.004
European Journal of Oncology Nursing, 17(6), 802-807. Churchill Livingstone

Purpose The Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire developed to assess the effect of EGFRI on patients. The FACT-EGFR-18 was translated into D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8343e3048def41090687ef4b93f05c0
https://doi.org/10.1016/j.ejon.2013.03.004

Zobrazit plný text záznamu

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review

Autor: Judith E. Raber-Durlacher, Christine B. Boers-Doets, Joel B. Epstein, Richard M. Logan, Mario E. Lacouture, Hans Gelderblom, Jan Ouwerkerk, Jan A.C. Brakenhoff

Publikováno v: The Oncologist, 17(1), 135-144. AlphaMed Press
Boers-Doets, C B, Epstein, J B, Raber-Durlacher, J E, Ouwerkerk, J, Logan, R M, Brakenhoff, J A, Lacouture, M E & Gelderblom, H 2012, ' Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review ', The Oncologist, vol. 17, no. 1, pp. 135-144 . https://doi.org/10.1634/theoncologist.2011-0111

Learning Objectives After completing this course, the reader will be able to: Describe the oral manifestations that can appear with TKI/mTORI.Describe the limitations of the current oral assessment tools in assessing these novel presentations and lis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa7351acddc4a729a113f25112f77531
https://hdl.handle.net/11245/1.372665

Zobrazit plný text záznamu

Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry☆

Autor: Ming Zhao, Sharyn D. Baker, Jan Ouwerkerk, Hans Gelderblom, Patton Minkin, Zhaoyuan Chen

Publikováno v: Journal of Chromatography B. 874:84-88

A rapid, sensitive and specific method was developed and validated using LC/MS/MS for determination of sunitinib in human plasma. Sample preparation involved a liquid-liquid extraction by the addition of 0.2 mL of plasma with 4.0 mL tert-butyl-methyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c43b03f42b5250bb12e2214f812e622
https://doi.org/10.1016/j.jchromb.2008.09.007

Zobrazit plný text záznamu

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

Autor: Henk-Jan Guchelaar, Hans Gelderblom, Sharyn D. Baker, Ming Zhao, Mats O. Karlsson, Johan W.R. Nortier, Alex Sparreboom, Jan Ouwerkerk, Nielka P. van Erp, Jing Li

Publikováno v: Clinical Cancer Research. 13:7394-7400

Purpose: To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib. Experimental Design: Imatinib pharmacokinetics were evaluated in cancer patients receiving the drug for at least 2 months,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f1195680b911365e283dea351d4fcf
https://doi.org/10.1158/1078-0432.ccr-07-0346

Zobrazit plný text záznamu

Interventions for skin reactions associated with targeted anticancer treatments

Autor: Christine B. Boers-Doets, Jan A.C. Brakenhoff, Jessica M. Langenhoff, William Bro, Esther J van Zuuren, Annemie Galimont, Theo Stijnen, Jan Ouwerkerk, Mario E. Lacouture, Hans W. R. Nortier

Publikováno v: The Cochrane Library

Reason for Withdrawal The current authors have relinquished responsibility for this protocol. It was published several years ago, and the Cochrane Skin Group have decided to withdraw it (Managing Editor, Cochrane Skin Group). To view the published ve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5403f2d91cce7114dd22dc72e7d6abd
https://doi.org/10.1002/14651858.cd009236.pub2

Zobrazit plný text záznamu

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma

Autor: Sjoerd Rodenhuis, Ron A. A. Mathot, H. J. Keizer, Jos H. Beijnen, Jan Ouwerkerk, Jan H.M. Schellens, T. Kerbusch

Publikováno v: European Journal of Clinical Pharmacology. 57:467-477

Objective: The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma. Methods: Twenty p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f898a951a2cb1716a0d0211353b7f1b4
https://doi.org/10.1007/s002280100322

Zobrazit plný text záznamu

Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review

Autor: Henk-Jan Guchelaar, F.A. de Jong, J. M. Baas, A.P.M. Lavrijsen, Hans Gelderblom, Jan Ouwerkerk, L. L. Krens

Publikováno v: Cancer Treatment Reviews
Cancer Treatment Reviews, 38(5), 505-514

Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequently result in skin toxicity, due to the expression of the E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b8607c0a80142ea2f375fda3f872c0b
https://hdl.handle.net/1887/98036

Zobrazit plný text záznamu

[A man with blisters on hand and feet]

Autor: A J Hans, Gelderblom, Jasper I, van der Rhee, Jan, Ouwerkerk

Publikováno v: Nederlands tijdschrift voor geneeskunde. 155(45)

A 41-year-old man with metastases of a gastrointestinal stroma tumour was treated with an angiogenesis inhibitor. He presented with a distinct painful erythematous hyperkeratotic bullous hand-foot skin reaction. This was thought to be caused by the o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5723f0d82d9f238152832b3ede821764
https://pubmed.ncbi.nlm.nih.gov/22085574

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání